William P McGuire

William P McGuire

UNVERIFIED PROFILE

Are you William P McGuire?   Register this Author

Register author
William P McGuire

William P McGuire

Publications by authors named "William P McGuire"

Are you William P McGuire?   Register this Author

45Publications

558Reads

40Profile Views

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.

Gynecol Oncol 2019 08 19;154(2):420-425. Epub 2019 Jun 19.

Department of Obstetrics and Gynecology, Peggy and Charles Stephenson Cancer Center - University of Oklahoma, Oklahoma City, OK 73104, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.05.013DOI Listing
August 2019

Co-occurring substance use disorder: The impact on treatment adherence in women with locally advanced cervical cancer.

Gynecol Oncol Rep 2019 May 27;28:116-119. Epub 2019 Mar 27.

Virginia Commonwealth University Health System, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2019.03.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460223PMC
May 2019

Treatment-Related Radiation Toxicity Among Cervical Cancer Patients.

Int J Gynecol Cancer 2018 09;28(7):1387-1393

Division of Gynecologic Oncology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000001309DOI Listing
September 2018

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future.

Front Oncol 2017 21;7:177. Epub 2017 Aug 21.

Division of Gynecologic Oncology, Virginia Commonwealth University, Main Hospital, Richmond, VA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2017.00177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566993PMC
August 2017

Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.

Cancer Biol Ther 2015 29;16(11):1660-70. Epub 2015 Sep 29.

a Department of Biochemistry and Molecular Biology ; Virginia Commonwealth University ; Richmond , VA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2015.1099769DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846137PMC
September 2016

Reply to T.j. Herzog et Al.

J Clin Oncol 2015 May 2;33(13):1512. Epub 2015 Mar 2.

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.3571DOI Listing
May 2015

Ovarian cancer and antiangiogenic therapy: caveat emptor.

J Clin Oncol 2014 Oct 15;32(30):3353-6. Epub 2014 Sep 15.

Inova Fairfax Hospital, Annandale, VA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.4574DOI Listing
October 2014

Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.

J Cancer 2014 Jan 1;5(1):25-30. Epub 2014 Jan 1.

4. Department of Medicine, Inova Fairfax Hospital, Falls Church, VA 22042, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.7810DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881218PMC
January 2014

HE4--another marker for gynecologic cancers: do we really need one?

Oncology (Williston Park) 2013 Jun;27(6):563, 566

Inova Fairfax Hospital, Falls Church, Virginia, USA.

View Article

Download full-text PDF

Source
June 2013

Another confirmation of the inactivity of topotecan in ovarian cancer.

J Natl Cancer Inst 2010 Oct 11;102(20):1523-4. Epub 2010 Oct 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djq387DOI Listing
October 2010

Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?

Expert Rev Anticancer Ther 2008 Jul;8(7):1135-47

Clinical Research Fellow, Clinical Research Branch, National Institute on Aging/NIH & Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.8.7.1135DOI Listing
July 2008

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

J Clin Oncol 2008 Jan 19;26(1):83-9. Epub 2007 Nov 19.

Department of Obstetrics and Gynecology, Gynecologic Oncology, Brooke Army Medical Center, Ft Sam Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.13.1953DOI Listing
January 2008

Ovarian cancer and the battle of the specialists.

J Clin Oncol 2007 Aug;25(23):3554-5; author reply 3557-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.12.5229DOI Listing
August 2007

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

J Clin Oncol 2007 Aug;25(24):3621-7

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brooke Army Medical Center, Ft Sam.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.10.2517DOI Listing
August 2007

Is it time for some new approaches for treating advanced ovarian cancer?

J Natl Cancer Inst 2006 Aug;98(15):1024-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djj321DOI Listing
August 2006

Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.

J Support Oncol 2003 Jul-Aug;1(2):131-8

Section of Cytokines and Targeted Therapies, Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
May 2006

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.

Gynecol Oncol 2006 Apr 2;101(1):55-61. Epub 2005 Nov 2.

Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care Program, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2005.09.036DOI Listing
April 2006

CASE 1. Testis: a sanctuary site in Merkel cell carcinoma.

J Clin Oncol 2006 Feb;24(6):1008-9

University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.01.7103DOI Listing
February 2006

CA-125 and early ovarian cancer: does this help the clinician or further muddy the water?

J Clin Oncol 2005 Sep 8;23(25):5862-4. Epub 2005 Aug 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.05.027DOI Listing
September 2005

Recurrent ovarian cancer.

Clin Adv Hematol Oncol 2005 Sep;3(9):723-36

Greenbaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA.

View Article

Download full-text PDF

Source
September 2005

Perioperative morbidity and the rush to chemotherapy.

J Clin Oncol 2005 Feb 21;23(4):665-6. Epub 2004 Dec 21.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.09.922DOI Listing
February 2005

Liposomal anthracycline treatment for ovarian cancer.

Semin Oncol 2004 Dec;31(6 Suppl 13):91-105

University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
December 2004

Progress in the management of gynecologic cancer: consensus summary statement.

J Clin Oncol 2003 May;21(10 Suppl):129s-132s

Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.04.003DOI Listing
May 2003

Current status of taxane and platinum-based chemotherapy in ovarian cancer.

J Clin Oncol 2003 May;21(10 Suppl):133s-135s

Oncology Service Line, Franklin Square Hospital, Baltimore, MD 21237, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.01.066DOI Listing
May 2003

Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.

Oncology (Williston Park) 2002 Oct;16(10 Suppl 11):31-6

Center for Oncology Research & Treatment Dallas, Texas, USA.

View Article

Download full-text PDF

Source
October 2002